Abstract
Hyperparathyroidism is a condition with elevated parathyroid hormone (PTH). The increase may be due to a) primary hyperparathyroidism which is caused by adenoma of one or more parathyroid glands or hyperplasia of all four glands, b) secondary hyperparathyroidism, which may be caused by deficiency in vitamin D or uremia, and 3) tertiary hyperparathyroidism, which most often is the result of a long-standing, severe secondary hyperparathyroidism, which has turned autonomous once the cause of the secondary hyperparathyroidism has been removed. Many new treatment options have been introduced in recent years. Cinacalcet is a calcium sensing receptor agonist, which by stimulating the receptor decreases PTH and calcium levels. It may be used in primary hyperparathyroidism, secondary hyperparathyroidism caused by uremia, which may not be controlled with calcium and activated vitamin D. It may also be used in tertiary hyperparathyroidism. Newer analogues of vitamin D such as paricalcitol have also been introduced, which may have an advantage over traditional compounds such as alphacalcidol and calcitriol.
Keywords: Alphacalcidol, calcitriol, cinacalcet, hyperparathyroidism, parathyroid hormone, paricalcitol, uremia, vitamin D, pregnancy
Current Drug Safety
Title: Medical Treatment of Primary, Secondary, and Tertiary Hyperparathyroidism
Volume: 6 Issue: 2
Author(s): Peter Vestergaard and Susanna vid Streym Thomsen
Affiliation:
Keywords: Alphacalcidol, calcitriol, cinacalcet, hyperparathyroidism, parathyroid hormone, paricalcitol, uremia, vitamin D, pregnancy
Abstract: Hyperparathyroidism is a condition with elevated parathyroid hormone (PTH). The increase may be due to a) primary hyperparathyroidism which is caused by adenoma of one or more parathyroid glands or hyperplasia of all four glands, b) secondary hyperparathyroidism, which may be caused by deficiency in vitamin D or uremia, and 3) tertiary hyperparathyroidism, which most often is the result of a long-standing, severe secondary hyperparathyroidism, which has turned autonomous once the cause of the secondary hyperparathyroidism has been removed. Many new treatment options have been introduced in recent years. Cinacalcet is a calcium sensing receptor agonist, which by stimulating the receptor decreases PTH and calcium levels. It may be used in primary hyperparathyroidism, secondary hyperparathyroidism caused by uremia, which may not be controlled with calcium and activated vitamin D. It may also be used in tertiary hyperparathyroidism. Newer analogues of vitamin D such as paricalcitol have also been introduced, which may have an advantage over traditional compounds such as alphacalcidol and calcitriol.
Export Options
About this article
Cite this article as:
Vestergaard Peter and vid Streym Thomsen Susanna, Medical Treatment of Primary, Secondary, and Tertiary Hyperparathyroidism, Current Drug Safety 2011; 6 (2) . https://dx.doi.org/10.2174/157488611795684703
DOI https://dx.doi.org/10.2174/157488611795684703 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prostaglandin E2 Receptors as Potential Bone Anabolic Targets – Selective EP4 Receptor Agonists
Current Molecular Pharmacology Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Editorial (Thematic Issue: Novel Therapeutic Strategies for Castration-resistant Prostate Cancer: Update and Future Perspectives)
Clinical Cancer Drugs Peptido-Targeting of the Mitochondrial Transition Pore Complex for Therapeutic Apoptosis Induction
Current Pharmaceutical Design A Highly Sensitive Fluorimetric Method for Determination of Cinacalcet Hydrochloride in Tablets and Plasma via Derivatization with 7-Chloro-4- nitrobenzoxadiazole
Current Analytical Chemistry The Effects of Bisphosphonates on the Bone Marrow Niche and Circulating and Disseminated Tumor Cells
Current Cancer Therapy Reviews Diagnosis of Alterations of Serum Calcium Metabolism
Medicinal Chemistry Renal Neoplasia in the Hyperparathyroidism-Jaw Tumor Syndrome
Current Molecular Medicine A Brief Introduction to Porphyrin Compounds used in Tumor Imaging and Therapies
Mini-Reviews in Medicinal Chemistry New Strategies in Treatment of Mineral and Bone Disorders and Associated Cardiovascular Disease in Patients with Chronic Kidney Disease
Recent Patents on Cardiovascular Drug Discovery Safety of Canagliflozin in Patients with Type 2 Diabetes
Current Drug Safety Pulmonary Disease in Beta-Thalassemia
Current Respiratory Medicine Reviews Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies
Current Neuropharmacology Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry The Fundamental Role of Stress Echo in Evaluating Coronary Artery Disease in Specific Patient Populations
Current Vascular Pharmacology Resisting the Sun with Vitamin D
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) V-ATPase Subunit Interactions: The Long Road to Therapeutic Targeting
Current Protein & Peptide Science Formulation and Application of Biodegradable Nanoparticles Based Biopharmaceutical Delivery - An Efficient Delivery System
Current Pharmaceutical Design Drug Delivery Systems Based on Titania Nanotubes and Active Agents for Enhanced Osseointegration of Bone Implants
Current Medicinal Chemistry